2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
7
Ovarian Neoplasms
6
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma, Ewing
4
Leukemia
4
Uterine Neoplasms
3
Uterine Cervical Neoplasms
3
Neoplasms
3
Multiple Myeloma
3
Kidney Neoplasms
3
Gliosarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Astrocytoma
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma, Follicular
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms
2
Brain Neoplasms
2
Thymoma
1
Small Cell Lung Carcinoma
1
Interventions
Filgrastim
20
Etoposide
20
Ifosfamide
19
Cyclophosphamide
18
Vincristine
13
Radiotherapy
13
Doxorubicin
13
Peripheral Blood Stem Cell Transplantation
12
Melphalan
12
Carboplatin
10
Busulfan
9
Topotecan
8
Temozolomide
8
Magnetic Resonance Spectroscopy
8
X-Rays
6
Thiotepa
6
Phantoms, Imaging
6
Irinotecan
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
trioctyl phosphine oxide
4
Mesna
4
Docetaxel
4
Dactinomycin
4
temsirolimus
3
etoposide phosphate
3
cixutumumab
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts